Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC

被引：0
|
作者：
Nassar, Amin
Mouw, Kent William
Liu, Chia-Jen
Lundgren, Kevin
Van Allen, Eliezer Mendel
Harshman, Lauren Christine
Pomerantz, Mark
Preston, Mark A.
Wei, Xiao X.
McGregor, Bradley Alexander
Choudhury, Atish Dipankar
Bellmunt, Joaquim
Choueiri, Toni K.
Kwiatkowski, David J.
Sonpavde, Guru
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Brookline, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] David Grant Med Ctr, Benicia, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4539
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Rao, Quan
    Li, Min
    Xu, Wei
    Pang, Kai
    Guo, XiaoBo
    Wang, Dong
    Liu, Jun
    Guo, Wei
    Zhang, ZhongTao
    HEPATOLOGY INTERNATIONAL, 2020, 14 (05) : 765 - 775
  • [42] PD1/PD-L1抑制剂治疗肿瘤
    赵宇飞
    陈晓
    李薇
    中国肿瘤生物治疗杂志, 2017, 24 (08) : 904 - 911
  • [43] PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review
    Adamczyk, Michal
    Krasowska, Dorota
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2021, 38 (06): : 925 - 930
  • [44] PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation
    Rosado, Flavia G.
    Coberly, Jared
    Gupta, Arjun
    John, George
    Naina, Harris
    Koduru, Prasad
    Chen, Weina
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2021, 51 (02): : 174 - 181
  • [45] PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
    Lingyu Tian
    Jiaqiang Ma
    Lijie Ma
    Bohao Zheng
    Longzi Liu
    Danjun Song
    Yining Wang
    Zhao Zhang
    Qiang Gao
    Kang Song
    Xiaoying Wang
    World Journal of Surgical Oncology, 18
  • [46] PD1/PD-L1 immunohistochemistry in thoracic oncology: Where are we?
    Hofman, Paul
    Ilie, Marius
    Lassalle, Sandra
    Long, Elodie
    Bence, Coraline
    Butori, Catherine
    Hofman, Veronique
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 39 - 45
  • [47] PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
    Tian, Lingyu
    Ma, Jiaqiang
    Ma, Lijie
    Zheng, Bohao
    Liu, Longzi
    Song, Danjun
    Wang, Yining
    Zhang, Zhao
    Gao, Qiang
    Song, Kang
    Wang, Xiaoying
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [48] PD1/PD-L1 therapy in metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Lemberger, Ursula
    Hassler, Melanie R.
    Fajkovic, Harun
    Schmidinger, Manuela
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 534 - 541
  • [49] Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy
    Villacampa, Guillermo
    Morgado, Pablo Cresta
    Navarro, Victor
    Viaplana, Cristina
    Dienstmann, Rodrigo
    CANCER TREATMENT REVIEWS, 2023, 116
  • [50] Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
    Simona Serratì
    Michele Guida
    Roberta Di Fonte
    Simona De Summa
    Sabino Strippoli
    Rosa Maria Iacobazzi
    Alessandra Quarta
    Ivana De Risi
    Gabriella Guida
    Angelo Paradiso
    Letizia Porcelli
    Amalia Azzariti
    Molecular Cancer, 21
12345